{"id":978582,"date":"2023-10-20T04:16:45","date_gmt":"2023-10-20T06:16:45","guid":{"rendered":"https:\/\/teknomers.com\/fr\/les-actions-de-daiichi-sankyo-grimpent-a-deux-chiffres-daiichi-sankyo-et-merck-annoncent-une-cooperation\/"},"modified":"2023-10-20T04:16:48","modified_gmt":"2023-10-20T06:16:48","slug":"les-actions-de-daiichi-sankyo-grimpent-a-deux-chiffres-daiichi-sankyo-et-merck-annoncent-une-cooperation","status":"publish","type":"post","link":"https:\/\/teknomers.com\/fr\/les-actions-de-daiichi-sankyo-grimpent-a-deux-chiffres-daiichi-sankyo-et-merck-annoncent-une-cooperation\/","title":{"rendered":"Les actions de DAIICHI SANKYO grimpent \u00e0 deux chiffres\u00a0: DAIICHI SANKYO et Merck annoncent une coop\u00e9ration"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<p>La soci\u00e9t\u00e9 pharmaceutique am\u00e9ricaine Merck &#038; Co. travaille avec DAIICHI SANKYO sur trois th\u00e9rapies potentielles contre le cancer.<\/p>\n<div>\n<p>Les deux soci\u00e9t\u00e9s ont convenu de d\u00e9velopper et de commercialiser conjointement les candidats m\u00e9dicaments Atritumab Deruxtecan, Ifinatamab Deruxtecan et Raludotatug Deruxtecan dans le monde entier.  L&#8217;accord s&#8217;\u00e9l\u00e8ve \u00e0 22 milliards de dollars et p\u00e8sera sur le quatri\u00e8me trimestre de Merck.\n<\/p>\n<p>L&#8217;action DAIICHI SANKYO a temporairement gagn\u00e9 14,22 pour cent \u00e0 4 088 yens \u00e0 Tokyo.\n<\/p>\n<p>(Dow Jones Newswires)<\/p>\n<\/div>\n<div id=\"\">\n<h2 class=\"headline headline--h4\">Produits \u00e0 effet de levier s\u00e9lectionn\u00e9s sur DAIICHI SANKYO<\/h2>\n<p>Avec les knock-outs, les investisseurs sp\u00e9culatifs peuvent participer de mani\u00e8re disproportionn\u00e9e aux mouvements de prix.  S\u00e9lectionnez simplement le levier que vous souhaitez et nous vous pr\u00e9senterons les produits ouverts adapt\u00e9s sur DAIICHI SANKYO<\/p>\n<p class=\"font-color-red display-none\" id=\"lvgCustomHandleInfo\">L&#8217;effet de levier doit \u00eatre compris entre 2 et 20<\/p>\n<p><span class=\"ad-hint ad-hint--right display-block\">Publicit\u00e9<\/span><\/div>\n<p>Sources d&#8217;images\u00a0: Katherine Welles \/ Shutterstock.com, Adam Michal Ziaja \/ Shutterstock.com<\/p>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.finanzen.net\/nachricht\/aktien\/milliarden-deal-daiichi-sankyo-aktie-springt-zweistellig-an-daiichi-sankyo-und-merck-kuendigen-kooperation-an-12940821\" rel=\"nofollow noopener\" target=\"_blank\">ttn-fr-28<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La soci\u00e9t\u00e9 pharmaceutique am\u00e9ricaine Merck &#038; Co. travaille avec DAIICHI SANKYO sur trois th\u00e9rapies potentielles contre le cancer. Les deux soci\u00e9t\u00e9s ont convenu de d\u00e9velopper et de commercialiser conjointement les candidats m\u00e9dicaments Atritumab Deruxtecan, Ifinatamab Deruxtecan et Raludotatug Deruxtecan dans le monde entier. L&#8217;accord s&#8217;\u00e9l\u00e8ve \u00e0 22 milliards de dollars et p\u00e8sera sur le quatri\u00e8me [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":978583,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[1964,6191,379,6876,120538,245,15596,65,87154,120539,196],"class_list":["post-978582","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance","tag-actions","tag-annoncent","tag-chiffres","tag-cooperation","tag-daiichi","tag-deux","tag-grimpent","tag-les","tag-merck","tag-sankyo","tag-une"],"_links":{"self":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/posts\/978582","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/comments?post=978582"}],"version-history":[{"count":0,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/posts\/978582\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/media\/978583"}],"wp:attachment":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/media?parent=978582"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/categories?post=978582"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/tags?post=978582"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}